Quick Answer
Nurix Therapeutics, Inc. reported Total Revenue of $83.98 million for the year ending 2025.
- Nurix Therapeutics, Inc. showed an increase of +54.0% in Total Revenue from 2024 to 2025.
- This data is from Nurix Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on January 28, 2026.
- XBRL data for this metric is available from 2019 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $9.23 million | Q2 2019: $9.44 million | Q3 2019: $10.58 million | Q4 2019: $1.86 million | Q1 2020: $2.86 million | Q2 2020: $4.18 million | Q3 2020: $4.09 million | Q4 2020: $6.69 million | Q1 2021: $5.01 million | Q2 2021: $7.09 million | Q3 2021: $10.25 million | Q1 2022: $9.62 million | Q2 2022: $11.43 million | Q3 2022: $10.79 million | Q1 2023: $12.69 million | Q2 2023: $30.68 million | Q2 2023: $30.68 million | Q3 2023: $18.47 million | Q3 2023: $18.47 million | Q1 2024: $16.59 million | Q1 2024: $16.59 million | Q2 2024: $12.09 million | Q3 2024: $12.59 million | Q1 2025: $18.45 million | Q2 2025: $44.06 million | Q3 2025: $7.89 million.
- Over the full 9 years of available data (2019 to 2025), Nurix Therapeutics, Inc.'s Total Revenue has grown by 169.9%.
- Historical annual values: Fiscal year 2025: $83.98 million | Fiscal year 2024: $54.55 million | Fiscal year 2023: $76.99 million | Fiscal year 2023: $76.99 million | Fiscal year 2022: $38.63 million | Fiscal year 2022: $38.63 million | Fiscal year 2021: $29.75 million | Fiscal year 2020: $17.82 million | Fiscal year 2019: $31.12 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: